Review
Cardiac & Cardiovascular Systems
Wei Wang, Hao Zheng
Summary: This review summarizes the role of miRNAs in the myocardial pathological process after MI, uncovering potential major target pathways and discussing the future direction of treatment with the combination of miRNAs and exosome nanocomplexes.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Medicine, Research & Experimental
Yuying Li, Chenghui Yan, Jiahui Fan, Zhiwei Hou, Yaling Han
Summary: The study shows that miR-221-3p inhibits angiogenesis of endothelial cells by targeting HIF-1α and that inhibition of miR-221-3p improves cardiac function of TAC-induced HF mice. Serum miR-221-3p may serve as a potential prognostic marker for HF.
LABORATORY INVESTIGATION
(2021)
Article
Cardiac & Cardiovascular Systems
Linfeng Li, Xiangwang He, Min Liu, Libing Yun, Bin Cong
Summary: This study found that cardiac miR-126-5p and miR-499a-5p were downregulated in CAD-SCD patients, and their combination had good diagnostic capabilities. These miRNAs are expected to serve as novel biomarkers for CAD-SCD and help differentiate the detailed causes in SCD cases.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Bharathi Priya Lohanathan, Baskaran Rathinasamy, Chih-Yang Huang, Vijaya Padma Viswanadha
Summary: This study evaluated the protective effect of neferine on doxorubicin-induced cardiac fibrosis and hypertrophy. The results showed that neferine reduced fibrosis, hypertrophy, and apoptosis in doxorubicin-treated cardiomyoblasts by modulating the expression levels of specific factors.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Jin Li, Ane M. Salvador, Guoping Li, Nedyalka Valkov, Olivia Ziegler, Ashish Yeri, Chun Yang Xiao, Bessie Meechoovet, Eric Alsop, Rodosthenis S. Rodosthenous, Piyusha Kundu, Tianxiao Huan, Daniel Levy, John Tigges, Alexander R. Pico, Ionita Ghiran, Michael G. Silverman, Xiangmin Meng, Robert Kitchen, Jiahong Xu, Kendall Van Keuren-Jensen, Ravi Shah, Junjie Xiao, Saumya Das
Summary: miR-30d can improve cardiac function and reduce fibrosis by targeting MAP4K4 and integrin alpha 5, showing a protective effect in ischemic heart failure. The communication of extracellular vesicle-contained miRNAs may provide a novel therapeutic target in heart failure treatment.
CIRCULATION RESEARCH
(2021)
Article
Medicine, Research & Experimental
Suman Dalal, Paige L. Shook, Mahipal Singh, Krishna Singh
Summary: This study investigates the cardioprotective effect of exogenous ubiquitin (UB) treatment in a mouse model of myocardial ischemia/reperfusion (I/R) injury. The results show that UB treatment improves heart function and reduces myocardial fibrosis, apoptosis, hypertrophy, and serum cytokine/chemokine levels.
Article
Biochemistry & Molecular Biology
Mengni Bao, Xiumeng Hua, Han Mo, Zhe Sun, Bo Xu, Xiao Chen, Mengda Xu, Xinjie Xu, Jiangping Song
Summary: This study investigated the molecular mechanism of hyperthyroidism-induced cardiomyopathy (HTC) and the effect of N-acetylcysteine (NAC) on the pathophysiology of HTC. It was found that NAC can alleviate the pathophysiology of HTC, possibly by regulating the ROS/Ca2+-dependent pathway.
Review
Medicine, Research & Experimental
Yu-Qing Tan, Jun Li, Heng-Wen Chen
Summary: Cardiovascular disease is a leading cause of death and disability, and its pathogenesis is complex and not fully understood. Mitochondria and cAMP signaling play important roles in cardiovascular function. Epac, as an effector of cAMP, is involved in various mechanisms of cardiovascular disease. This article systematically discusses the mechanism of action of Epac in cardiovascular diseases, providing insights and a basis for treatment and research.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Deepika Dasari, Srashti Gopal Goyal, Anuhya Penmetsa, Dharmarajan Sriram, Arti Dhar
Summary: This study evaluated the effect of canagliflozin on SGLT1 expression in an animal model of diabetic cardiomyopathy (DCM) and its associated effects. The results showed that canagliflozin protects the DCM heart by inhibiting myocardial SGLT-1 and associated hypertrophy, fibrosis, and apoptosis. Therefore, developing novel pharmacological inhibitors targeting SGLT-1 could be a better strategy for treating DCM and associated cardiovascular complications.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Kwon-Woo Kim, Keetae Kim, Hee-Jin Kim, Byeol- Kim, Myungin Baek, Byung-Chang Suh
Summary: Recently emerged miRNAs, specifically the miR-106b family members, have been found to regulate the expression of the KCNQ2 K+ channel protein by binding to its mRNA. The levels of miR-106b decrease while KCNQ2 protein levels increase after birth. Overexpression of miR-106b leads to reduced KCNQ2 protein levels, while inhibition of miR-106b results in increased levels of KCNQ2.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Plant Sciences
Meixu Wan, Kunkun Yin, Jing Yuan, Shiyan Ma, Qing Xu, Dekun Li, Hui Gao, Xiangbo Gou
Summary: The Yiqi Fumai lyophilized injection (YQFM) demonstrated protective effects in cardiac hypertrophy by inhibiting cardiomyocyte apoptosis, regulating autophagy pathway, and activating the PI3K/AKT/mTOR pathway to attenuate cardiac hypertrophy.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Lara Ottaviani, Rio P. Juni, Ricardo C. de Abreu, Marida Sansonetti, Vasco Sampaio-Pinto, Julie Halkein, Jana C. Hegenbarth, Nadja Ring, Kevin Knoops, Jordy M. M. Kocken, Carlos de Jesus, Auriane C. Ernault, Hamid El Azzouzi, Frank Ruhle, Serve Olieslagers, Hugo Fernandes, Lino Ferreira, Luca Braga, Monika Stoll, Diana S. Nascimento, Leon J. de Windt, Paula A. da Costa Martins
Summary: miR-200c-3p in extracellular vesicles secreted by cardiac myocytes plays a crucial role in the communication between cardiac cells and endothelial cells, affecting cardiac function and disease development.
Article
Medicine, Research & Experimental
Jingyao Yang, Long Li, Xiaoxiao Zheng, Zhaoyang Lu, Hua Zhou
Summary: As a sodium-glucose transporter 2 inhibitor (SGLT2i), Dapagliflozin (DAPA) has been widely recognized for its cardioprotective benefits. This study explored the underlying mechanisms of DAPA on angiotensin II (Ang II)-induced myocardial hypertrophy and found that DAPA treatment can alleviate Ang II-induced cardiac injury, hypertrophy, and fibrosis. It also reversed the changes in HIF-1a and SIRT1 levels induced by Ang II. Overall, activating the SIRT1/HIF-1a signaling pathway may be an effective therapeutic target for pathological cardiac hypertrophy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Chemistry, Multidisciplinary
Fang-fang Ren, Lin Zhao, Xian-yun Jiang, Jing-jing Zhang, Jia-min Gou, Xiao-yu Yu, Shu-jin Wu, Lei Li
Summary: Apoptosis, or programmed cell death, plays a critical role in the development of heart failure. Sphingosylphosphorylcholine (SPC), a bioactive sphingolipid, has been shown to inhibit apoptosis in myofibroblasts, non-muscle cells in the heart. In this study, the researchers investigated the role of the SPC receptor, calmodulin (CaM), in cardiomyocyte apoptosis and the associated signaling pathways. They found that SPC administration improved survival rate, cardiac hypertrophy, and cardiac fibrosis in mice with pressure overload-induced heart failure. In cardiomyocytes, SPC treatment inhibited cardiomyocyte hypertrophy, fibroblast-to-myofibroblast transition, and cell apoptosis. This was accompanied by reduced levels of pro-apoptotic proteins and phosphorylation of CaM, JNK, and p38, as well as increased levels of a cardiomyocyte-protective protein. The protective effect of SPC was annulled by a compound that increased CaM function. The researchers also demonstrated that SPC-mediated inhibition of cardiomyocyte apoptosis involved the regulation of p38 and JNK phosphorylation, which was downstream of CaM. These findings provide new evidence for SPC regulation of cardiomyocyte apoptosis and suggest it as a potential therapeutic target for cardiac remodeling following stress overload.
ACTA PHARMACOLOGICA SINICA
(2023)
Article
Cell Biology
Irene Salamon, Elena Biagini, Paolo Kunderfranco, Roberta Roncarati, Manuela Ferracin, Nevio Taglieri, Elena Nardi, Noemi Laprovitera, Luciana Tomasi, Marisa Santostefano, Raffaello Ditaranto, Giovanni Vitale, Elena Cavarretta, Antonio Pisani, Eleonora Riccio, Valeria Aiello, Irene Capelli, Gaetano La Manna, Nazzareno Galie, Letizia Spinelli, Gianluigi Condorelli
Summary: miR-184 is a circulating biomarker associated with AFD that changes after ERT. Assessing its level in plasma could be clinically valuable in improving the prediction of cardiac damage in AFD patients.
CELL DEATH & DISEASE
(2021)
